Utility of serum tartrate-resistant acid phosphatase (TRACP5b) as a bone resorption marker in patients with chronic kidney disease: Independence from renal dysfunction

Clinical Endocrinology

Volumn 69, Issue 2, 2008, Pages 189-196

  Yamada, Shinsuke ^a   Inaba, Masaaki ^a   Kurajoh, Masafumi ^a   Shidara, Kaori ^a   Imanishi, Yasuo ^a   Ishimura, Eiji ^a   Nishizawa, Yoshiki ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALKALINE PHOSPHATASE; BIOLOGICAL MARKER; COLLAGEN TYPE 1; OSTEOCALCIN; PARATHYROID HORMONE; TELOPEPTIDE;

ACID PHOSPHATASE BLOOD LEVEL; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; BODY MASS; BONE TURNOVER; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS LINKING; ENZYME ASSAY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; OSSIFICATION; OSTEOLYSIS; PARATHYROID DISEASE; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY;

ACID PHOSPHATASE; AGED; BIOLOGICAL MARKERS; BONE RESORPTION; CASE-CONTROL STUDIES; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; ISOENZYMES; KIDNEY; MALE; MIDDLE AGED; PARATHYROID HORMONE; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; SENSITIVITY AND SPECIFICITY;

EID: 47549099246     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2008.03187.x     Document Type: Article

References (51)

1. Piraino, B., Chen, T., Cooperstein, L., Segre, G. Puschett, J. (1988) Fractures and vertebral bone mineral density in patients with renal osteodystrophy. Clinical Nephrology, 30, 57 62.
2. Ballanti, P., Coen, G., Mazzaferro, S., Taggi, F., Giustini, M., Calabria, S., Ferrannini, M. Bonucci, E. (2001) Histomorphometric assessment of bone turnover in uraemic patients: comparison between activation frequency and bone formation rate. Histopathology, 38, 571 583.
3. Maeno, Y., Inaba, M., Okuno, S., Yamakawa, T., Ishimura, E. Nishizawa, Y. (2005) Serum concentrations of cross-linked N-telopeptides of type I collagen: new marker for bone resorption in hemodialysis patients. Clinical Chemistry, 51, 2312 2317.
4. Okuno, S., Inaba, M., Kitatani, K., Ishimura, E., Yamakawa, T. Nishizawa, Y. (2005) Serum levels of C-terminal telopeptide of type I collagen: a useful new marker of cortical bone loss in hemodialysis patients. Osteoporosis International, 16, 501 509.
5. Nagasue, K., Inaba, M., Okuno, S., Kitatani, K., Imanishi, Y., Ishimura, E., Miki, T., Kim, M. Nishizawa, Y. (2003) Serum N-terminal midfragment vs. intact osteocalcin immunoradiometric assay as markers for bone turnover and bone loss in hemodialysis patients. Biomedicine and Pharmacotherapy, 57, 98 104.
6. Chaki, O., Yoshikata, I., Kikuchi, R., Nakayama, M., Uchiyama, Y., Hirahara, F. Gorai, I. (2000) The predictive value of biochemical markers of bone turnover for bone mineral density in postmenopausal Japanese women. Journal of Bone and Mineral Research, 8, 1537 1544.
7. Ueda, M., Inaba, M., Okuno, S., Maeno, Y., Ishimura, E., Yamakawa, T. Nishizawa, Y. (2005) Serum BAP as the clinically useful marker for predicting BMD reduction in diabetic hemodialysis patients with low PTH. Life Sciences, 22, 77, 1130 1139.
8. Franke, S., Lehmann, G., Abendroth, K., Hein, G. Stein, G. (1998) PICP as bone formation and NTx as bone resorption maker in patients with chronic renal failure. European Journal of Medical Research, 21, 81 88.
9. Müller, A., Stein, G., Lehmann, G. Hein, G. (1999) Investigations of bone turnover in renal osteopathy. European Journal of Medicine Research, 25, 78 84.
10. Halleen, J.M., Alatalo, S.L., Suominen, H., Cheng, S., Janckila, A.J. Vaananen, H.K. (2000) Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. Journal of Bone and Mineral Research, 15, 1337 1345.
11. Vaananen, H.K., Zhao, H., Mulari, M. Halleen, J.M. (2000) The cell biology of osteoclast function. Journal of Cell Science, 113, 377 381.
12. Chu, P., Chao, T.Y., Lin, Y.F., Janckila, A.J. Yam, L.T. (2003) Correlation between histomorphometric parameters of bone resorption and serum type 5b tartrate-resistant acid phosphatase in uremic patients on maintenance hemodialysis. American Journal of Kidney Diseases, 541, 1052 1059.
13. Halleen, J.M., Ylipahkala, H., Alatalo, S.L., Janckila, A.J., Heikkinen, J.E., Suominen, H., Cheng, S. Vaananen, H.K. (2002) serum tartrate-resistant acid phosphatase 5b, but not 5a, correlates with other markers of bone turnover and bone mineral density. Calcified Tissue International, 71, 20 25.
14. Halleen, J.M., Hentunen, T.A., Karp, M., Kakonen, S.M., Pettersson, K. Vaananen, H.K. (1998) Characterization of serum tartrate-resistant acid phosphatase and development of a direct two-site immunoassay. Journal of Bone and Mineral Research, 13, 683 687.
15. Chamberlain, P., Compston, J., Cox, T.M., Havman, A.R., Imrie, R.C., Revnolds, K. Holmes, S.D. (1995) Generation and characterization of monoclonal antibodies to human type-5 tartrate-resistant acid phosphatase: development of a specific immunoassay of the isoenzyme in serum. Clinical Chemistry, 41, 1495 1499.
16. Miyazaki, S., Igarashi, M., Nagata, A., Tominaga, Y., Onodera, K. Komoda, T. (2003) Development of immunoassays for type-5 tartrate-resistant acid phosphatase in human serum. Clinica Chimica Acta, 329, 109 115.
17. Nakasato, Y.R., Janckila, A.J., Halleen, J.M., Vaananen, H.K., Walton, S.P. Yam, L.T. (1999) Clinical significance of immunoassays for type-5 tartrate-resistant acid phosphatase. Clinical Chemistry, 45, 2150 2157.
18. Hannon, R.A., Clowes, J.A., Eagleton, A.C., Al Hadari, A., Eastell, R. Blumsohn, A. (2004) Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform as a marker of bone resorption. Bone, 34, 187 194.
19. Inaba, M., Terada, M., Nishizawa, Y., Shioi, A., Ishimura, E., Otani, S. Morii, H. (1999) Protective effect of an aldose reductase inhibitor against bone loss in galactose-fed rats: possible involvement of the polyol pathway in bone metabolism. Metabolism, 48, 904 909.
20. MDRD 1992) Study group the modification of diet in renal disease study: design, methods, and results from the feasibility study. American Journal of Kidney Diseases, 20, 18 33.
21. Babazono, T., Hanai, K., Suzuki, K., Kiuchi, Y., Inoue, A., Tanaka, M., Tanaka, N., Hase, M., Ishii, A. Iwamoto, Y. (2006) Lower haemoglobin level and subsequent decline in kidney function in type 2 diabetic adults without clinical albuminuria. Diabetologia, 49, 1387 1393.
22. Chudleigh, R.A., Dunseath, G., Evans, W., Harvey, J.N., Evans, P., Ollerton, R. Owens, D.R. (2007) How reliable is estimation of glomerular filtration rate diagnosis of type 2 diabetes? Diabetes Care, 30, 300 305.
23. Ohashi, T., Igarashi, Y., Mochizuki, Y., Miura, T., Inaba, N., Katayama, K., Tomonaga, T. Nomura, F. (2007) Development of a novel fragments absorbed immunocapture enzyme assay system for tartrate-resistant acid phosphatase 5b. Clinical Chemistry Acta, 376, 205 212.
24. Scariano, J.K., Glew, R.H., Bou-Serhal, C.E., Clemens, J.D., Garry, P.J. Baumgartner, R.N. (1998) Serum levels of cross-linked N-telopeptides and aminoterminal propeptides of type I collagen indicate low bone mineral density in elderly women. Bone, 23, 471 477.
25. Gomez, B. Jr., Ardakani, S., Ju, J., Jenkins, D., Cerelli, M.J., Daniloff, G.Y. Kung, V.T. (1995) Monoclonal antibody assay for measuring bone-specific alkaline phosphatase activity in serum. Clinical Chemistry, 41, 1560 1566.
26. Kumeda, Y., Inaba, M., Tahara, H., Kurioka, Y., Ishikawa, T., Morii, H. Nishizawa, Y. (2000) Persistent increase in bone turnover in Graves' patients with subclinical hyperthyroidism. Journal of Clinical Endocrinology and Metabolism, 85, 4157 4161.
27. Inaba, M., Nishizawa, Y., Mita, K., Kumeda, Y., Emoto, M., Kawagishi, T., Ishimura, E., Nakatsuka, K., Shioi, A. Morii, H. (1999) Poor glycemic control impairs the response of biochemical parameters of bone formation and resorption to exogenous 1,25-dihydroxyvitamin D3 in patients with type 2 diabetes. Osteoporosis International, 9, 525 531.
28. Takahashi, M., Kushida, K., Nagano, A. Inoue, T. (2000) Comparison of the analytical and clinical performance characteristics of an N-MID versus an intact osteocalcin immunoradiometric assay. Clinca Chimica Acta, 294, 67 76.
29. Gao, P., Scheibel, S., D'Amour, P., John, M.R., Rao, S.D., Schmidt-Gayk, H. Cantor, T.L. (2001) Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1-84: implications for improvement of accurate assessment of parathyroid function. Journal of Bone and Mineral Research, 16, 605 614.
30. Inaba, M., Nakatsuka, K., Imanishi, Y., Watanabe, M., Mamiya, Y., Ishimura, E. Nishizawa, Y. (2004) Technical and clinical characterization of the Bio-PTH (1-84) immunochemiluminometric assay and comparison with a second-generation assay for parathyroid hormone. Clinical Chemistry, 50, 385 390.
31. Reichel, H., Esser, A., Roth, H.-J. Schmidt-Gayk, H. (2003) Influence of PTH assay methodology on differential diagnosis of renal bone disease. Nephrology Dialysis Transplantation, 18, 759 768.
32. Roth, H.J. (2000) Elecsys parathyroid hormone (PTH) not detecting the large PTH fragment hPTH (7-84)? Clinical Laboratory, 46, 295 299.
33. Inomata, K., Yamashita, H., Yamamoto, A., Karashita, M., Adachi, M., Yamashita, Y., Kawamoto, H. Noguchi, S. (2004) Influence of 25-hydroxyvitamin D concentration on the reference range of intact PTH. Osteoporosis Japan, 12, 449 456.
34. Yamasita, H., Motomiya, Y., Uchida, K. Akizawa, T. (2002) Development and clinical application of Whole PTH (PTH1-84) kit. Japanese Journal of Medicine and Pharmaceutical Science, 48, 243 247.
35. Nishizawa, Y., Nakamura, T., Ohta, H., Kushida, K., Gorai, I., Shiraki, M., Fukunaga, M., Hosoi, T., Miki, T., Chaki, O., Ichimura, S., Nakatsuka, K. Miura, M. for the Committee on the Guidelines for the Use of Biochemical Markers of Bone Turnover in Osteoporosis Japan Osteoporosis Society (2005) Guidelines for the use of biochemical markers of bone turnover in Osteoporosis (2004). Journal of Bone and Mineral Metabolism, 23, 97 104.
36. Yoshimura, N., Nakatsuka, K., Saitou, S., Nishizawa, Y., Uchiyama, M. Miura, M. (2002) Serum cross-linked N-telopeptide of type I collagen (NTX) and serum amino-terminal propeptide of type I procollagen (PINP) in residents of a rural community in Japan. Reference value classified by age and sex. Osteoporosis Japan, 10, 171 175.
37. Iki, M., Akiba, T., Matsumoto, T., Nishino, H., Kagamimori, S., Kagawa, Y., Yoneshima, H. JPOS Study Group (2004) Reference database of biochemical markers of bone turnover for the Japanese female population. Japanese Population-based Osteoporosis (JPOS) Study Osteoporosis International, 15, 981 991.
38. Ueda, M., Inaba, M., Okuno, S., Nagasue, K., Kitatani, K., Ishimura, E., Shimizu, M., Miki, T., Kim, M. Nishizawa, Y. (2002) Clinical usefulness of the serum N-terminal propeptide of type I collagen as a marker of bone formation in hemodialysis patients. American Journal of Kidney Disease, 40, 802 809.
39. Nakanishi, S., Kazama, J.J., Shigematsu, T., Iwasaki, Y., Cantor, T.L., Kurosawa, T. Fukagawa, M. (2001) Comparison of intact PTH assay and whole PTH assay in long-term dialysis patients. American Journal of Kidney Diseases, 38, S172 S174.
40. Inaba, M., Okuno, S., Imanishi, Y., Ueda, M., Yamakawa, T., Ishimura, E. Nishizawa, Y. (2005) Significance of Bio-intact PTH (1-84) assay in hemodialysis patients. Osteoporosis International, 16, 517 525.
41. Iwasaki, Y., Yamato, H., Nii-Kono, T., Fujieda, A., Uchida, M., Hosokawa, A., Motojima, M. Fukagawa, M. (2006) Insufficiency of PTH action on bone in uremia. Kidney International, 70, 34 36.
42. Komarova, S.V. (2005) Mathematical model of paracrine interactions between osteoclasts and osteoblasts predicts anabolic action of parathyroid hormone on bone. Endocrinology, 146, 3589 3595.
43. Tahtela, R., Seppanen, J., Laitinen, K., Katajamaki, A., Risteli, J. Valimaki, M.J. (2005) Serum tartrate-resistant acid phosphatase 5b in monitoring bisphosphonate treatment with clodronate: a comparison with urinary N-terminal telopeptide of type I collagen and serum type I procollagen amino-terminal propeptide. Osteoporosis International, 16, 1109 1116.
44. Ichinose, Y., Tanaka, H., Inoue, M., Mochizuki, S., Tsuda, E. Seino, Y. (2004) Osteoclastogenesis inhibitory factor/osteoprotegerin reduced bone loss induced by mechanical unloading. Calcified Tissue International, 75, 338 343.
45. Salingcarnboriboon, R., Tsuji, K., Komori, T., Nakashima, K., Ezura, Y. Noda, M. (2006) Runx2 is a target of mechanical unloading to alter osteoblastic activity and bone formation in vivo. Endocrinology, 147, 2296 2305.
46. Hannon, R.A., Clowes, J.A., Eagleton, A.C., Al Hadari, A., Eastell, R. Blumsohn, A. (2004) Clinical performance of immunoreactive tartrate-resistant acid phosphatase isoform 5b as a marker of bone resorption. Bone, 34, 187 194.
47. Gerdhem, P., Ivaska, K.K., Alatalo, S.L., Halleen, J.M., Hellman, J., Isaksson, A., Pettersson, K., Vaananen, H.K., Akesson, K. Obrant, K.J. (2004) Biochemical markers of bone metabolism and prediction of fracture in elderly women. Journal of Bone and Mineral Research, 19, 386 393.
48. Halleen, J.M., Alatalo, S.L., Janckila, A.J., Woitge, H.W., Seibel, M.J. Vaananen, H.K. (2001) Serum tartrate-resistant acid phosphatase 5b is a specific and sensitive marker of bone resorption. Clinical Chemistry, 47, 597 600.
49. Habermann, B., Eberhardt, C., Feld, M., Zichner, L. Kurth, A.A. (2007) Tartrate-resistant acid phosphatase 5b (TRAP 5b) as a marker of osteoclast activity in the early phase after cementless total hip replacement. Acta Orthopaedica, 78, 221 225.
50. Henriksen, K., Tanko, L.B., Qvist, P., Delmas, P.D., Christiansen, C. Karsdal, M.A. (2007) Assessment of osteoclast number and function. Application in the development of new and improved treatment modalities for bone diseases. Osteoporosis International, 18, 681 685.
51. Chao, T.Y., Lin, Y.F., Janckila, A.J. Yam, L.T. (2003) Correlation between histomorphometric parameters of bone resorption and serum type 5b tartrate-resistant acid phosphatase in uremic patients on maintenance hemodialysis. American Journal of Kidney Diseases, 41, 1052 1059.